Cardiology Update

NOVEMBER 19, 2023

The ORBITA-2 trial ( NCT03742050 ) investigated the efficacy of Percutaneous Coronary Intervention (PCI) compared to placebo in 301 patients with stable angina. At the 12-week mark, the PCI group exhibited a significantly lower mean angina score (2.9) compared to the placebo group (5.6; odds ratio, 2.21; 95% CI, 1.41-3.47;

Angina 52

Angina Ischemia Article Research 52

Cardiology Update

JANUARY 14, 2024

The perplexing landscape of angina with nonobstructive coronary arteries (ANOCA) encompasses diverse pathophysiological entities, including coronary microvascular disease (CMD), coronary artery spasm, and the enigmatic myocardial bridging (MB).

Exercise 119

Exercise Ischemia Angina Physiology 119

Cardiology Update

MARCH 4, 2024

The primary outcome was a composite of death from any cause, myocardial infarction, or hospitalization for unstable angina at 2 years. The analysis composed of participants with multivessel or left main CAD.

Coronary Artery Disease 111

Coronary Artery Disease Myocardial Infarction Angina Article 111

Cardiology Update

APRIL 9, 2024

The primary endpoint consisted of a composite of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina. However, CSR did significantly reduce the number of daily angina episodes compared to placebo. of patients in the PCI group compared to 3.4% in the medical therapy group.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

Cardiology Update

APRIL 30, 2024

Recently published in EuroIntervention, additional analysis from the ISCHEMIA trial evaluated three main aspects: first, the association between participant sex and the likelihood of undergoing revascularization among those randomized to the INV arm; second, the risk of the ISCHEMIA primary composite outcome (cardiovascular death, myocardial infarction (..)

Coronary Artery Disease 119

Coronary Artery Disease Ischemia Outcomes Cardiac Arrest 119